The endocannabinoid system and its therapeutic exploitation

By V. Di Marzo, M. Bifulco, L. Petrocellis. Nature reviews. Drug discovery, 2004

1,077 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/2330eaa777f28e14a537a940f498f1dcc55de773

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. V. Di Marzo
2. P. Pacher
3. S. Batkai
4. George Kunos

In Pharmacology

1. V. Di Marzo
2. George Kunos
3. P. Pacher
4. S. Batkai
5. G. Marsicano
6. B. Lutz

In Surgery

1. P. Pacher
2. S. Batkai
3. George Kunos
4. V. Di Marzo

Citations in the corpus

• The emerging role of the endocannabinoid system in endocrine regulation and energy balance. (2006, background): “An interesting aspect of endocannabinoid activity is the rapid induction of their synthesis, receptor activation, and degradation (3, 102).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…marijuana and the recent resurgence of interest in its medicinal properties have been the subject of excellent reviews (Mechoulam, 1986; Iversen, 2000; Di Marzo et al., 2004; Howlett et al., 2004; Pertwee, 2005a; Piomelli, 2005; Di Marzo and Petrocellis, 2006; Mackie, 2006; Pagotto et al., 2006).”
• Paracetamol: new vistas of an old drug. (2006, background): “6 ìg h mL in fasted and fed healthy volunteers, respectively (207); food reduced the maximum concentration of oral paracetamol by 49% (207) [when paracetamol is coadministered with food, the absorption rate of the drug is decreased; for rapid relief of pain, paracetamol should not be taken with food”
• Targeting the endocannabinoid system: to enhance or reduce? (2008, background): “However, new generations of endocannabinoid-manipulating drugs designed almost entirely in silico or screened out of libraries of compounds have been developed and are either being tested in clinical trials or already on the marke”
• Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. (2006, background): “This is not surprising in consideration of the fact that these compounds are biosynthesized and metabolized via different pathways (1, 2).”
• The endocannabinoid system controls key epileptogenic circuits in the hippocampus. (2006, neutral): “…2001; van der Stelt et al., 2002; Lutz, 2004) and the proposed therapeutic exploitation of this system for the treatment of several diseases (Di Marzo et al., 2004; Mackie, 2006), it is of central importance to determine in detail which neuronal subtypes are controlled by the endogenous…”